RATIONALE: Psilocybin (PSI) microdosing, defined as a repeated administration of sub-perceptual doses, has gained increasing attention as a potential therapeutic strategy for affective and anxiety disorders. However, some molecular mechanisms, particularly regarding epigenetic regulation in the medial prefrontal cortex (mPFC), remain poorly understood. OBJECTIVES: Therefore, the present study...
Repeated low-dose psilocybin is being developed as a scalable outpatient treatment for mood and anxiety disorders, but chronic exposure raises concern because psilocin binds the cardiac serotonin 5-HT2B receptor, whose sustained agonism causes drug-induced valvular heart disease (VHD). We evaluated this risk using an exposure–response model that incorporates functional efficacy and exposure...
Psilocybin is a classic psychedelic known to alter subjective experience and induce lasting psychological changes, including increased cognitive flexibility and reduced rigid self-related beliefs. Contextual factors, including preparatory mental states, are thought to play a key role in shaping these effects. Compassion imagery, which engages care-affiliative motivational systems, may represent...
Psilocybin shows potential in neuropsychiatric disorders but has a complex relationship with epilepsy and seizures. We reviewed literature up to November 2025 to identify studies relevant to psilocybin's effects on seizures and epilepsy, including our research on serotonergic modulation. Core studies addressing the research question and supplementary mechanistic evidence were included for...
Background Psilocybin-assisted therapy is continuing to show significant positive effects for palliative cancer patients, both in reducing symptoms and improving one’s sense of hope and meaning. Most research has focused on individual therapy models, limiting access and overlooking potential community-based benefits. Methods This qualitative study describes the results of patients experiencing...
Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...
Background In natural product psilocybin retreats, "dose" is commonly defined by grams of dried mushrooms, despite substantial batch-to-batch variability in psilocybin content. This limits safety predictability and undermines reproducibility and between-study comparability. We report an observational field evaluation of an existing, ICH Q2(R1)-validated rapid colorimetric/photometric assay...
Abstract Psilocybin is a serotonergic psychedelic drug with emerging therapeutic applications, yet its actions under glutamatergic dysfunction, and relevance to schizophrenia and associated psychiatric disorders, remain unclear. We examined the acute and long-lasting effects of psilocybin (1 mg/kg, intraperitoneal) on behavioral and neural outcomes in the metabotropic glutamate receptor 5...
Background: When administered alongside monitoring and support, psilocybin has shown promise in the treatment of multiple psychiatric conditions. However, the contribution and nature of participant support in the context of psychedelic trials are much debated. Aims: We sought to further illustrate the structure and format of the monitoring and support used in Compass Pathfinder Ltd (Compass)...